Pyxis Oncology Inc. (PYXS)

Business: Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.

IPO Date: 08-Oct-2021

Co-Founder & Independent Chairman: Mr. John L. Flavin M.B.A., MBA, Ph.D.

CEO, Pres & Director: Dr. Lara S. Sullivan M.D., MBA

Listing: NASDAQ: PYXS

Country: United States

Headquarters: Cambridge, MA

Website: https://www.pyxisoncology.com

Market cap: $80.07 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-84.87 Mln

Cash: $247.09 Mln

Total Debt: $0.00 Mln

Insider's Holding: 18.77%

Liquidity: Low

52 Week range: $1.96 - 19.00

Shares outstanding: 32,817,100